



## Clinical trial results:

### A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors

#### Summary

EudraCT number	2020-001908-42
Trial protocol	NO HU DE PL PT IT
Global end of trial date	25 July 2023

#### Results information

Result version number	v2 (current)
This version publication date	21 September 2024
First version publication date	04 August 2024
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	V937-013
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04521621
WHO universal trial number (UTN)	-
Other trial identifiers	jRCT2033200191: jRCT

Notes:

#### Sponsors

Sponsor organisation name	Merck Sharp & Dohme LLC
Sponsor organisation address	126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@msd.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@msd.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 July 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 July 2023
Global end of trial reached?	Yes
Global end of trial date	25 July 2023
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study is to evaluate the safety, tolerability, and efficacy in participants with advanced/metastatic or recurrent malignancies who receive gebasaxturev (V937) in combination with pembrolizumab (MK-3475). The primary objective for Part 1 is to evaluate the objective response rate, and the primary objective for Part 2 is to determine the safety and tolerability of gebasaxturev administered in combination with pembrolizumab. With Amendment 4, this study will be terminated once all participants who have completed or discontinued gebasaxturev treatment and are only receiving pembrolizumab may be enrolled in a pembrolizumab extension study, if available, to continue pembrolizumab monotherapy for up to 35 cycles from first pembrolizumab dose on V937-013.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 October 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 6
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Spain: 16
Country: Number of subjects enrolled	France: 12
Country: Number of subjects enrolled	Hungary: 2
Country: Number of subjects enrolled	Israel: 9
Country: Number of subjects enrolled	Japan: 2
Country: Number of subjects enrolled	Norway: 7
Country: Number of subjects enrolled	Peru: 2
Country: Number of subjects enrolled	Poland: 1
Country: Number of subjects enrolled	Portugal: 4
Country: Number of subjects enrolled	Taiwan: 11
Country: Number of subjects enrolled	United States: 3
Worldwide total number of subjects	76
EEA total number of subjects	43

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	43
From 65 to 84 years	24
85 years and over	9

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

76 participants were allocated and 75 participants received study intervention. Enrollment was also planned to Part 2 Cohort D (participants with hepatocellular carcinoma (HCC) solid tumors) and Part 2 Cohort E (participants with gastric carcinoma solid tumors); however, the study was terminated before enrollment into these arms began.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Part 1, Cohort A: Triple-Negative Breast Cancer
------------------	---

Arm description:

Participants with triple-negative breast cancer (TNBC) solid tumors received 3 X 10<sup>8</sup> 50% tissue culture infectious dose (TCID<sub>50</sub>) of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	MK-3475 KEYTRUDA®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.

Investigational medicinal product name	Gebasaxturev
Investigational medicinal product code	
Other name	Coxsackievirus A21(CVA21) Formerly known asCAVATAK® CAV21 V937
Pharmaceutical forms	Solution for infusion
Routes of administration	Intratumoral use

Dosage and administration details:

Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.

<b>Arm title</b>	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma
------------------	---

Arm description:

Participants with head and neck squamous cell carcinoma (HNSCC) solid tumors received 3 X 10<sup>8</sup> TCID<sub>50</sub> of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	MK-3475 KEYTRUDA®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.	
Investigational medicinal product name	Gebasaxturev
Investigational medicinal product code	
Other name	Coxsackievirus A21(CVA21) Formerly known asCAVATAK® CAV21 V937
Pharmaceutical forms	Solution for infusion
Routes of administration	Intratumoral use
Dosage and administration details:	
Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.	
<b>Arm title</b>	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma
Arm description:	
Participants with cutaneous squamous cell carcinoma (cSCC) solid tumors received 3 X 10 <sup>8</sup> TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	MK-3475 KEYTRUDA®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.	
Investigational medicinal product name	Gebasaxturev
Investigational medicinal product code	
Other name	Coxsackievirus A21(CVA21) Formerly known asCAVATAK® CAV21 V937
Pharmaceutical forms	Solution for infusion
Routes of administration	Intratumoral use
Dosage and administration details:	
Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.	
<b>Arm title</b>	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Arm description:	
Participants with solid tumors with liver metastases received 3 X 10 <sup>7</sup> TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	MK-3475 KEYTRUDA®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:	
Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.	
Investigational medicinal product name	Gebasaxturev
Investigational medicinal product code	
Other name	Coxsackievirus A21(CVA21) Formerly known asCAVATAK® CAV21 V937
Pharmaceutical forms	Solution for infusion
Routes of administration	Intratumoral use
Dosage and administration details:	
Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.	
<b>Arm title</b>	Part 2 Dose Level 2, Solid Tumors + Liver Metastases
Arm description:	
Participants with solid tumors with liver metastases received 1 X 10 <sup>8</sup> TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	MK-3475 KEYTRUDA®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.	
Investigational medicinal product name	Gebasaxturev
Investigational medicinal product code	
Other name	Coxsackievirus A21(CVA21) Formerly known asCAVATAK® CAV21 V937
Pharmaceutical forms	Solution for infusion
Routes of administration	Intratumoral use
Dosage and administration details:	
Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.	
<b>Arm title</b>	Part 2 Dose Level 3, Solid Tumors + Liver Metastases
Arm description:	
Participants with solid tumors with liver metastases received 3 X 10 <sup>8</sup> TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	MK-3475 KEYTRUDA®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.	
Investigational medicinal product name	Gebasaxturev
Investigational medicinal product code	
Other name	Coxsackievirus A21(CVA21) Formerly known asCAVATAK® CAV21

	V937
Pharmaceutical forms	Solution for infusion
Routes of administration	Intratumoral use

Dosage and administration details:

Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.

Number of subjects in period 1	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma
Started	22	14	17
Treated	21	14	17
Completed	0	0	0
Not completed	22	14	17
Consent withdrawn by subject	-	-	1
Death	17	8	8
Allocated in error without study intervention	1	-	-
Study Terminated by Sponsor	4	6	8

Number of subjects in period 1	Part 2 Dose Level 1, Solid Tumors + Liver Metastases	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases
Started	6	3	14
Treated	6	3	14
Completed	0	0	0
Not completed	6	3	14
Consent withdrawn by subject	1	-	-
Death	5	2	7
Allocated in error without study intervention	-	-	-
Study Terminated by Sponsor	-	1	7

## Baseline characteristics

### Reporting groups

Reporting group title	Part 1, Cohort A: Triple-Negative Breast Cancer
Reporting group description: Participants with triple-negative breast cancer (TNBC) solid tumors received 3 X 10 <sup>8</sup> 50% tissue culture infectious dose (TCID50) of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Reporting group title	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma
Reporting group description: Participants with head and neck squamous cell carcinoma (HNSCC) solid tumors received 3 X 10 <sup>8</sup> TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Reporting group title	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma
Reporting group description: Participants with cutaneous squamous cell carcinoma (cSCC) solid tumors received 3 X 10 <sup>8</sup> TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Reporting group title	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Reporting group description: Participants with solid tumors with liver metastases received 3 X 10 <sup>7</sup> TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Reporting group title	Part 2 Dose Level 2, Solid Tumors + Liver Metastases
Reporting group description: Participants with solid tumors with liver metastases received 1 X 10 <sup>8</sup> TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Reporting group title	Part 2 Dose Level 3, Solid Tumors + Liver Metastases
Reporting group description: Participants with solid tumors with liver metastases received 3 X 10 <sup>8</sup> TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	

Reporting group values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma
Number of subjects	22	14	17
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	17	9	3
From 65-84 years	5	5	5
85 years and over	0	0	9

Age Continuous Units: years arithmetic mean standard deviation	55.5 ± 11.5	59.7 ± 13.1	80.6 ± 12.8
Sex: Female, Male Units: participants			
Female	22	2	6
Male	0	12	11
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	7	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	20	7	14
More than one race	2	0	0
Unknown or Not Reported	0	0	3
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	4	0	0
Not Hispanic or Latino	18	14	13
Unknown or Not Reported	0	0	4

<b>Reporting group values</b>	Part 2 Dose Level 1, Solid Tumors + Liver Metastases	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases
Number of subjects	6	3	14
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	5	2	7
From 65-84 years	1	1	7
85 years and over	0	0	0
Age Continuous Units: years arithmetic mean standard deviation	54.7 ± 12.5	58.3 ± 8.3	57.8 ± 14.1
Sex: Female, Male Units: participants			
Female	3	2	10
Male	3	1	4
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	2	4

Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	5	1	8
More than one race	0	0	0
Unknown or Not Reported	0	0	2
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	6	3	11
Unknown or Not Reported	0	0	3

Reporting group values	Total		
Number of subjects	76		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	43		
From 65-84 years	24		
85 years and over	9		
Age Continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: participants			
Female	45		
Male	31		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	14		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	0		
White	55		
More than one race	2		
Unknown or Not Reported	5		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	4		
Not Hispanic or Latino	65		
Unknown or Not Reported	7		

## End points

### End points reporting groups

Reporting group title	Part 1, Cohort A: Triple-Negative Breast Cancer
Reporting group description: Participants with triple-negative breast cancer (TNBC) solid tumors received $3 \times 10^8$ 50% tissue culture infectious dose (TCID50) of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Reporting group title	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma
Reporting group description: Participants with head and neck squamous cell carcinoma (HNSCC) solid tumors received $3 \times 10^8$ TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Reporting group title	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma
Reporting group description: Participants with cutaneous squamous cell carcinoma (cSCC) solid tumors received $3 \times 10^8$ TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Reporting group title	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Reporting group description: Participants with solid tumors with liver metastases received $3 \times 10^7$ TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Reporting group title	Part 2 Dose Level 2, Solid Tumors + Liver Metastases
Reporting group description: Participants with solid tumors with liver metastases received $1 \times 10^8$ TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	
Reporting group title	Part 2 Dose Level 3, Solid Tumors + Liver Metastases
Reporting group description: Participants with solid tumors with liver metastases received $3 \times 10^8$ TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.	

### Primary: Part 1: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator

End point title	Part 1: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator <sup>[1]</sup>
End point description: ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions and no new lesions) or a Partial Response (PR: $\geq 30\%$ decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. The analysis population consisted of all allocated participants in Part 1 with a baseline scan that demonstrated measurable disease and who received at least 1 dose of study intervention.	
End point type	Primary
End point timeframe: Up to approximately 30 months	

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analyses were planned for this endpoint.

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	14	17	0 <sup>[2]</sup>
Units: Percentage of Participants				
number (confidence interval 95%)	0.0 (0.0 to 16.1)	35.7 (12.8 to 64.9)	64.7 (38.3 to 85.8)	( to )

Notes:

[2] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[3]</sup>	0 <sup>[4]</sup>		
Units: Percentage of Participants				
number (confidence interval 95%)	( to )	( to )		

Notes:

[3] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

[4] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants who Experienced a Dose-Limiting Toxicity (DLT)

End point title	Number of Participants who Experienced a Dose-Limiting Toxicity (DLT) <sup>[5]</sup>
-----------------	--

End point description:

The following toxicities during DLT evaluation period were considered a DLT, if assessed by investigator to be possibly, probably, or definitely related to treatment: Grade (Gr) 4 nonhematologic toxicity; Gr 4 hematologic toxicity lasting ≥7 days, except Gr 3 thrombocytopenia (if associated with clinically significant bleeding) or any grade febrile neutropenia; nonhematologic adverse event (AE) ≥ Gr 3 (with exceptions); Gr 3 or 4 nonhematologic lab abnormality (if medical intervention is required, leads to hospitalization, or persists for >1 week); drug-related toxicity that causes a >2 week delay in Cycle 2 initiation; drug-related toxicity that causes treatment discontinuation or missed dosage of gebasaxturev; or Gr 5 toxicity. The analysis population included all allocated participants in Part 2 who received at least 1 dose of study treatment who met the criteria for DLT evaluability (e.g. finished Cycle 1 without a DLT or experienced a DLT in Cycle 1).

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 (28-day cycle)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analyses were planned for this endpoint.

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[6]</sup>	0 <sup>[7]</sup>	0 <sup>[8]</sup>	6
Units: Participants				1

Notes:

[6] - Per protocol, only the participants in Part 2 were analyzed in this outcome measure.

[7] - Per protocol, only the participants in Part 2 were analyzed in this outcome measure.

[8] - Per protocol, only the participants in Part 2 were analyzed in this outcome measure.

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	14		
Units: Participants	0	1		

## Statistical analyses

No statistical analyses for this end point

## Primary: Part 2: Number of Participants Who Experienced One or More Adverse Events (AEs)

End point title	Part 2: Number of Participants Who Experienced One or More Adverse Events (AEs) <sup>[9]</sup>
-----------------	--

End point description:

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The analysis population included all allocated participants in Part 2 who received study intervention.

End point type	Primary
----------------	---------

End point timeframe:

Up to approximately 29 months

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analyses were planned for this endpoint.

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[10]</sup>	0 <sup>[11]</sup>	0 <sup>[12]</sup>	6
Units: Participants				6

Notes:

[10] - Per protocol, only participants in Part 2 were analyzed in this outcome measure.

[11] - Per protocol, only participants in Part 2 were analyzed in this outcome measure.

[12] - Per protocol, only participants in Part 2 were analyzed in this outcome measure.

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	14		
Units: Participants	2	14		

## Statistical analyses

No statistical analyses for this end point

### Primary: Part 2: Number of Participants Who Discontinued Study Intervention Due to an AE

End point title	Part 2: Number of Participants Who Discontinued Study Intervention Due to an AE <sup>[13]</sup>
-----------------	---

End point description:

An AE was defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The analysis population included all allocated participants in Part 2 who received study intervention.

End point type	Primary
----------------	---------

End point timeframe:

Up to approximately 10 months

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analyses were planned for this endpoint.

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[14]</sup>	0 <sup>[15]</sup>	0 <sup>[16]</sup>	6
Units: Participants				0

Notes:

[14] - Per protocol, only participants in Part 2 were analyzed in this outcome measure

[15] - Per protocol, only participants in Part 2 were analyzed in this outcome measure

[16] - Per protocol, only participants in Part 2 were analyzed in this outcome measure

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	14		
Units: Participants	0	1		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1: Number of Participants Who Experienced One or More AEs

End point title	Part 1: Number of Participants Who Experienced One or More AEs
-----------------	--

End point description:

An AE was defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The analysis population included all allocated participants in Part 1 who received study intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 30 months

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	14	17	0 <sup>[17]</sup>
Units: Participants	19	14	17	

Notes:

[17] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[18]</sup>	0 <sup>[19]</sup>		
Units: Participants				

Notes:

[18] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

[19] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1: Number of Participants Who Discontinued Study Intervention Due to an AE

End point title	Part 1: Number of Participants Who Discontinued Study
-----------------	---

## End point description:

An AE was defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The analysis population included all allocated participants in Part 1 who received study intervention.

End point type	Secondary
----------------	-----------

## End point timeframe:

Up to approximately 23 months

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	14	17	0 <sup>[20]</sup>
Units: Participants	1	3	3	

## Notes:

[20] - Per protocol, only participants in Part 1 were analyzed in this outcome measure

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[21]</sup>	0 <sup>[22]</sup>		
Units: Participants				

## Notes:

[21] - Per protocol, only participants in Part 1 were analyzed in this outcome measure

[22] - Per protocol, only participants in Part 1 were analyzed in this outcome measure

## Statistical analyses

No statistical analyses for this end point

## Secondary: Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by Investigator

End point title	Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by Investigator
-----------------	--

## End point description:

PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by investigator. Per RECIST 1.1, PD is defined as  $\geq 20\%$  increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of  $\geq 5$  mm. The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. A value of 9999 indicates that the upper limit not reached at time of data cut-off due to insufficient number of participants with an event. The analysis population consisted of all allocated participants in Part 1 with a baseline scan that demonstrated measurable disease and who received at least 1 dose of study intervention.

End point type	Secondary
----------------	-----------

## End point timeframe:

Up to approximately 30 months

<b>End point values</b>	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	14	17	0 <sup>[23]</sup>
Units: Months				
median (confidence interval 95%)	2.1 (1.5 to 3.1)	3.3 (1.7 to 9999)	15.4 (2.4 to 9999)	( to )

Notes:

[23] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

<b>End point values</b>	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[24]</sup>	0 <sup>[25]</sup>		
Units: Months				
median (confidence interval 95%)	( to )	( to )		

Notes:

[24] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

[25] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Response (DOR) per RECIST 1.1 as Assessed by Investigator

End point title	Duration of Response (DOR) per RECIST 1.1 as Assessed by Investigator
-----------------	---

End point description:

For participants who demonstrated a confirmed immune-based Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR:  $\geq 30\%$  decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. For this study, RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection did not render a lesion non-evaluable. A value of 9999 indicates that the median and upper limit were not reached at time of data cut-off due to insufficient number of responding participants with relapse. The analysis population consisted of all allocated participants in Part 1 who experienced a confirmed CR or PR with a baseline scan that demonstrated measurable disease and who received at least 1 dose of study intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 30 months

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[26]</sup>	5	11	0 <sup>[27]</sup>
Units: Months				
median (confidence interval 95%)	( to )	9999 (4.4 to 9999)	9999 (4.6 to 9999)	( to )

Notes:

[26] - No participants in Part 1, Cohort A were eligible for analysis.

[27] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[28]</sup>	0 <sup>[29]</sup>		
Units: Months				
median (confidence interval 95%)	( to )	( to )		

Notes:

[28] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

[29] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

## Statistical analyses

No statistical analyses for this end point

## Secondary: PFS per Response Evaluation Criteria in Solid Tumors 1.1 for Immune-Based Therapeutics (iRECIST) as Assessed by Investigator

End point title	PFS per Response Evaluation Criteria in Solid Tumors 1.1 for Immune-Based Therapeutics (iRECIST) as Assessed by Investigator
-----------------	--

End point description:

PFS was defined as the time from first dose of study treatment to the first documented immune-based confirmed progressive disease (iCPD) or death due to any cause, whichever occurs first as assessed by investigator. Per iRECIST, iCPD was defined as worsening of any existing cause of progression, or the appearance of any other cause of progression, relative to the initial appearance of progressive disease by RECIST 1.1. A value of 9999 indicates that the upper limit not reached at time of data cut-off due to insufficient number of participants with an event. The analysis population consisted of all allocated participants in Part 1 with a baseline scan that demonstrated measurable disease and who received at least 1 dose of study intervention.

End point type	Secondary
End point timeframe:	
Up to approximately 30 months	

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	14	17	0 <sup>[30]</sup>
Units: Months				
median (confidence interval 95%)	3.3 (1.3 to 4.3)	8.2 (2.1 to 9999)	20.4 (3.3 to 9999)	( to )

Notes:

[30] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[31]</sup>	0 <sup>[32]</sup>		
Units: Months				
median (confidence interval 95%)	( to )	( to )		

Notes:

[31] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

[32] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

## Statistical analyses

No statistical analyses for this end point

## Secondary: DOR per iRECIST as Assessed by Investigator

End point title	DOR per iRECIST as Assessed by Investigator
End point description:	
For participants who demonstrated confirmed CR (disappearance of all target lesions and non-target lesions) or PR ( $\geq 30\%$ decrease in the sum of diameters of target lesions) per RECIST 1.1 or immune-based Complete Response (iCR: Disappearance of all target lesions) or immune-based Partial Response (iPR: $\geq 30\%$ decrease in the sum of diameters of target lesions) after a single PD per iRECIST, DOR was defined as the time from the first documented CR or PR, or iCR or an iPR, as assessed by investigator, until progressive disease or death, whichever occurs first. A value of 9999 indicates that the median and upper limit were not reached at time of data cut-off due to insufficient number of responding participants with relapse. The analysis population consisted of all allocated participants in Part 1 who experienced a confirmed response (CR, PR, iCR or iPR) with a baseline scan that demonstrated measurable disease and who received at least 1 dose of study intervention.	
End point type	Secondary
End point timeframe:	
Up to approximately 30 months	

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[33]</sup>	6	11	0 <sup>[34]</sup>
Units: Months				

median (confidence interval 95%)	( to )	9999 (4.4 to 9999)	9999 (4.6 to 9999)	( to )
----------------------------------	--------	--------------------	--------------------	--------

Notes:

[33] - No participants in Part 1, Cohort A were eligible for analysis.

[34] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[35]</sup>	0 <sup>[36]</sup>		
Units: Months				
median (confidence interval 95%)	( to )	( to )		

Notes:

[35] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

[36] - Per protocol, only participants in Part 1 were analyzed in this outcome measure.

## Statistical analyses

No statistical analyses for this end point

## Secondary: ORR per iRECIST as Assessed by Investigator

End point title	ORR per iRECIST as Assessed by Investigator
-----------------	---

End point description:

ORR was defined as the percentage of participants who had confirmed responses assessed using RECIST 1.1 before PD or an immune-based Complete Response (iCR: Disappearance of all target lesions) or an immune-based Partial Response (iPR:  $\geq 30\%$  decrease in the sum of diameters of target lesions) after a single PD per iRECIST as assessed by investigator. The analysis population consisted of all participants with a baseline scan that demonstrated measurable disease and who were administered at least one dose of study intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 30 months

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	14	17	6
Units: Percentage of Participants				
number (confidence interval 95%)	0.0 (0.0 to 16.1)	42.9 (17.7 to 71.1)	64.7 (38.3 to 85.8)	16.7 (0.4 to 64.1)

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
------------------	--	--	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	14		
Units: Percentage of Participants				
number (confidence interval 95%)	0.0 (0.0 to 70.8)	0.0 (0.0 to 23.2)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

OS was defined as the time from first dose of study intervention to death due to any cause. The analysis population consisted of all allocated participants in Part 1 with a baseline scan that demonstrated measurable disease and who received at least 1 dose of study intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 30 months

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	14	17	0 <sup>[37]</sup>
Units: Months				
median (confidence interval 95%)	7.5 (4.3 to 15.0)	11.8 (3.0 to 9999)	20.4 (3.3 to 9999)	( to )

Notes:

[37] - Per protocol, only participants in Part 1 were analyzed in this outcome measure

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[38]</sup>	0 <sup>[39]</sup>		
Units: Months				
median (confidence interval 95%)	( to )	( to )		

Notes:

[38] - Per protocol, only participants in Part 1 were analyzed in this outcome measure

[39] - Per protocol, only participants in Part 1 were analyzed in this outcome measure

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 2: ORR per RECIST 1.1 as Assessed by Investigator

End point title	Part 2: ORR per RECIST 1.1 as Assessed by Investigator
-----------------	--

End point description:

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions and no new lesions) or a Partial Response (PR:  $\geq 30\%$  decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator. For this study, RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. The analysis population consisted of all allocated participants in Part 2 with a baseline scan that demonstrated measurable disease and who received at least 1 dose of study intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 29 months

End point values	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[40]</sup>	0 <sup>[41]</sup>	0 <sup>[42]</sup>	6
Units: Percentage of Participants				
number (confidence interval 95%)	( to )	( to )	( to )	16.7 (0.4 to 64.1)

Notes:

[40] - Per protocol, only participants in Part 2 were analyzed for this outcome measure.

[41] - Per protocol, only participants in Part 2 were analyzed for this outcome measure.

[42] - Per protocol, only participants in Part 2 were analyzed for this outcome measure.

End point values	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 2 Dose Level 3, Solid Tumors + Liver Metastases		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	14		
Units: Percentage of Participants				
number (confidence interval 95%)	0.0 (0.0 to 70.8)	0.0 (0.0 to 23.2)		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to approximately 30 months

Adverse event reporting additional description:

Deaths (all-causes) includes all allocated participants. Serious and Other AE tables include all allocated participants who received at least 1 dose of study drug. Per protocol, MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" and "Disease progression" unrelated to drug were excluded as AEs.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

### Reporting groups

Reporting group title	Part 1, Cohort A: Triple-Negative Breast Cancer
-----------------------	---

Reporting group description:

Participants with triple-negative breast cancer (TNBC) solid tumors received 3 X 10<sup>8</sup> 50% tissue culture infectious dose (TCID<sub>50</sub>) of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.

Reporting group title	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma
-----------------------	---

Reporting group description:

Participants with head and neck squamous cell carcinoma (HNSCC) solid tumors received 3 X 10<sup>8</sup> TCID<sub>50</sub> of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.

Reporting group title	Part 2 Dose Level 3, Solid Tumors + Liver Metastases
-----------------------	--

Reporting group description:

Participants with solid tumors with liver metastases received 3 X 10<sup>8</sup> TCID<sub>50</sub> of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.

Reporting group title	Part 2 Dose Level 1, Solid Tumors + Liver Metastases
-----------------------	--

Reporting group description:

Participants with solid tumors with liver metastases received 3 X 10<sup>7</sup> TCID<sub>50</sub> of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.

Reporting group title	Part 2 Dose Level 2, Solid Tumors + Liver Metastases
-----------------------	--

Reporting group description:

Participants with solid tumors with liver metastases received 1 X 10<sup>8</sup> TCID<sub>50</sub> of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.

Reporting group title	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma
-----------------------	---

Reporting group description:

Participants with cutaneous squamous cell carcinoma (cSCC) solid tumors received 3 X 10<sup>8</sup> TCID<sub>50</sub> of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 was 28 days, and cycles 2-35 were 21 days.

Serious adverse events	Part 1, Cohort A: Triple-Negative Breast Cancer	Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma	Part 2 Dose Level 3, Solid Tumors + Liver Metastases
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 21 (19.05%)	8 / 14 (57.14%)	3 / 14 (21.43%)

number of deaths (all causes)	18	8	7
number of deaths resulting from adverse events	0	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Infected neoplasm			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Troponin increased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Cervical vertebral fracture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic seroma			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			

subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Polyneuropathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
General physical health deterioration			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 21 (0.00%)	2 / 14 (14.29%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	2 / 21 (9.52%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract haemorrhage			

subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Stevens-Johnson syndrome			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lichenoid keratosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19 pneumonia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			

subjects affected / exposed	0 / 21 (0.00%)	2 / 14 (14.29%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Septic shock			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part 2 Dose Level 1, Solid Tumors + Liver Metastases	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 6 (66.67%)	1 / 3 (33.33%)	6 / 17 (35.29%)
number of deaths (all causes)	5	2	8
number of deaths resulting from adverse events	0	0	3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Infected neoplasm			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Troponin increased			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Cervical vertebral fracture			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic seroma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac failure congestive			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Polyneuropathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Encephalopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
General physical health deterioration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Stevens-Johnson syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lichenoid keratosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19 pneumonia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	<b>Part 1, Cohort A: Triple-Negative Breast Cancer</b>	<b>Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma</b>	<b>Part 2 Dose Level 3, Solid Tumors + Liver Metastases</b>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 21 (85.71%)	14 / 14 (100.00%)	14 / 14 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 21 (0.00%)	2 / 14 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	2	0
Haemangioma of spleen			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Melanocytic naevus			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Tumour pain			
subjects affected / exposed	1 / 21 (4.76%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	1	1	0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Embolism			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	2 / 21 (9.52%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	2	0	1
General disorders and administration site conditions			
Influenza like illness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	5
Fatigue			

subjects affected / exposed	2 / 21 (9.52%)	3 / 14 (21.43%)	4 / 14 (28.57%)
occurrences (all)	8	3	5
Facial pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Discomfort			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	4 / 21 (19.05%)	1 / 14 (7.14%)	1 / 14 (7.14%)
occurrences (all)	6	1	1
Asthenia			
subjects affected / exposed	2 / 21 (9.52%)	1 / 14 (7.14%)	3 / 14 (21.43%)
occurrences (all)	2	1	5
Injection site bruising			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Pyrexia			
subjects affected / exposed	6 / 21 (28.57%)	1 / 14 (7.14%)	5 / 14 (35.71%)
occurrences (all)	10	2	8
Pain			
subjects affected / exposed	4 / 21 (19.05%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	4	0	0
Oedema peripheral			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Oedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Swelling face			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Injection site pruritus			

subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	2	0	0
Injection site pain			
subjects affected / exposed	2 / 21 (9.52%)	1 / 14 (7.14%)	2 / 14 (14.29%)
occurrences (all)	5	2	5
Injection site oedema			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Injection site inflammation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Injection site erythema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Breast pain			
subjects affected / exposed	4 / 21 (19.05%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	4	0	0
Pelvic discomfort			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Perineal pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Respiratory, thoracic and mediastinal disorders			
Hiccups			
subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
Cough			
subjects affected / exposed	5 / 21 (23.81%)	1 / 14 (7.14%)	2 / 14 (14.29%)
occurrences (all)	5	1	2
Dyspnoea			

subjects affected / exposed	3 / 21 (14.29%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	3	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Haemoptysis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Lower respiratory tract congestion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Orthopnoea			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Productive cough			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 21 (0.00%)	3 / 14 (21.43%)	0 / 14 (0.00%)
occurrences (all)	0	3	0
Stridor			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Anxiety			

subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Confusional state			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hallucination, visual			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 21 (0.00%)	2 / 14 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	2	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	4 / 21 (19.05%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	4	0	1
Amylase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	4 / 21 (19.05%)	0 / 14 (0.00%)	3 / 14 (21.43%)
occurrences (all)	4	0	3
Bilirubin conjugated increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Blood bilirubin increased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	2 / 14 (14.29%)
occurrences (all)	1	0	2
Blood creatine increased			

subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 21 (14.29%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	3	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Blood urea increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
C-reactive protein increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
CD4 lymphocytes increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 21 (9.52%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	2	0	1
Lymphocyte count decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Neutrophil count increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Thyroxine free increased			

subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Thyroxine increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Troponin T increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
White blood cell count decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Protein total decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Skin wound			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Nasal injury			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Limb injury			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Fibula fracture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Stoma complication			

subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Arthropod sting subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Spinal compression fracture subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	1 / 14 (7.14%) 1
Cardiac disorders			
Tachycardia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Bradycardia subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Atrial fibrillation subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Angina pectoris subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	1 / 14 (7.14%) 1	2 / 14 (14.29%) 2
Cerebrovascular accident subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1
Encephalopathy			

subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Headache			
subjects affected / exposed	2 / 21 (9.52%)	2 / 14 (14.29%)	3 / 14 (21.43%)
occurrences (all)	6	2	4
Hypoaesthesia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Neuropathy peripheral			
subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	3 / 14 (21.43%)
occurrences (all)	0	0	3
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 21 (23.81%)	0 / 14 (0.00%)	2 / 14 (14.29%)
occurrences (all)	5	0	3
Hyperleukocytosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			

subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Deafness subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Exophthalmos subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Lacrimation increased subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Gastrointestinal disorders Anorectal discomfort subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1
Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	1 / 14 (7.14%) 2
Abdominal pain subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 2	1 / 14 (7.14%) 1	3 / 14 (21.43%) 3
Ascites subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1
Constipation			

subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	2 / 14 (14.29%)
occurrences (all)	0	1	2
Diarrhoea			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	3 / 14 (21.43%)
occurrences (all)	0	2	3
Dry mouth			
subjects affected / exposed	2 / 21 (9.52%)	1 / 14 (7.14%)	1 / 14 (7.14%)
occurrences (all)	2	1	1
Dysphagia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Epigastric discomfort			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Eructation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	5 / 21 (23.81%)	2 / 14 (14.29%)	5 / 14 (35.71%)
occurrences (all)	8	2	9
Odynophagia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Oral pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Salivary gland pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vomiting			

subjects affected / exposed occurrences (all)	3 / 21 (14.29%) 3	0 / 14 (0.00%) 0	4 / 14 (28.57%) 9
Toothache subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Tongue geographic subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1
Skin and subcutaneous tissue disorders			
Hyperhidrosis subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1
Acne subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Actinic keratosis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Blister subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Dermatitis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Dermatitis bullous subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Night sweats subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	4 / 14 (28.57%) 4	0 / 14 (0.00%) 0
Rash subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	3 / 14 (21.43%) 4	3 / 14 (21.43%) 3

Rash macular subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Skin haemorrhage subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Vitiligo subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Skin erosion subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Renal and urinary disorders Chronic kidney disease subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Nocturia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 14 (0.00%) 0	0 / 14 (0.00%) 0
Endocrine disorders Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Thyroiditis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 4	6 / 14 (42.86%) 6	0 / 14 (0.00%) 0
Hyperthyroidism subjects affected / exposed occurrences (all)	5 / 21 (23.81%) 5	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0
Musculoskeletal and connective tissue disorders			

Muscle spasms			
subjects affected / exposed	1 / 21 (4.76%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	3	1	0
Arthralgia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	4 / 14 (28.57%)
occurrences (all)	0	2	5
Back pain			
subjects affected / exposed	2 / 21 (9.52%)	1 / 14 (7.14%)	3 / 14 (21.43%)
occurrences (all)	2	1	3
Bone pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
Musculoskeletal pain			
subjects affected / exposed	2 / 21 (9.52%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Myalgia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	3	0	4
Neck pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	1 / 21 (4.76%)	1 / 14 (7.14%)	1 / 14 (7.14%)
occurrences (all)	1	1	1
Infections and infestations			
Bacteraemia			

subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Skin infection			
subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Rhinitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pneumonia aspiration			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Pneumonia			
subjects affected / exposed	0 / 21 (0.00%)	2 / 14 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	2	0
Oral candidiasis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Myiasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Gingivitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
COVID-19			

subjects affected / exposed	0 / 21 (0.00%)	5 / 14 (35.71%)	0 / 14 (0.00%)
occurrences (all)	0	5	0
Viral infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Urinary tract infection			
subjects affected / exposed	2 / 21 (9.52%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	2	0	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	2 / 14 (14.29%)
occurrences (all)	1	0	2
Hypercalcaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 21 (0.00%)	2 / 14 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	2	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	1	2	0
Hypomagnesaemia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 14 (0.00%)	0 / 14 (0.00%)
occurrences (all)	2	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 14 (7.14%)	0 / 14 (0.00%)
occurrences (all)	1	1	0
Hyponatraemia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 14 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	3

<b>Non-serious adverse events</b>	Part 2 Dose Level 1, Solid Tumors + Liver Metastases	Part 2 Dose Level 2, Solid Tumors + Liver Metastases	Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma
Total subjects affected by non-serious adverse events subjects affected / exposed	6 / 6 (100.00%)	2 / 3 (66.67%)	17 / 17 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Haemangioma of spleen subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Melanocytic naevus subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Tumour pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	3 / 17 (17.65%) 3
Vascular disorders Hypotension subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Embolism subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Hypertension subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
General disorders and administration site conditions Influenza like illness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	3 / 6 (50.00%) 3	0 / 3 (0.00%) 0	4 / 17 (23.53%) 4
Facial pain			

subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Face oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Chills			
subjects affected / exposed	3 / 6 (50.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	3	0	1
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	4 / 17 (23.53%)
occurrences (all)	0	0	4
Injection site bruising			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	2 / 6 (33.33%)	1 / 3 (33.33%)	2 / 17 (11.76%)
occurrences (all)	2	1	2
Pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Swelling face			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Injection site pruritus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Injection site pain			

subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	2 / 17 (11.76%)
occurrences (all)	3	0	2
Injection site oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Injection site inflammation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Injection site erythema			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Breast pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Pelvic discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Perineal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Hiccups			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	2 / 17 (11.76%)
occurrences (all)	2	0	2
Dyspnoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Dyspnoea exertional			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Haemoptysis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract congestion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Orthopnoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	2 / 17 (11.76%)
occurrences (all)	0	0	2
Rhinorrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Stridor			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	2 / 17 (11.76%)
occurrences (all)	0	0	2
Confusional state			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Hallucination, visual			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Insomnia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	2 / 17 (11.76%)
occurrences (all)	0	0	2
Amylase increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	2 / 17 (11.76%)
occurrences (all)	0	1	2
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	3 / 17 (17.65%)
occurrences (all)	0	0	3
Bilirubin conjugated increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	2 / 17 (11.76%)
occurrences (all)	0	0	2
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Blood creatine increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Blood creatine phosphokinase increased			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Blood urea increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
CD4 lymphocytes increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Neutrophil count decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Neutrophil count increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Platelet count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Thyroxine free increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Thyroxine increased			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Troponin T increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Weight decreased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Protein total decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Skin wound			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	2 / 17 (11.76%)
occurrences (all)	0	0	2
Skin abrasion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Nasal injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Fibula fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Stoma complication			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Arthropod sting			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Spinal compression fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Bradycardia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Atrial fibrillation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Angina pectoris			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Cerebrovascular accident			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Encephalopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Headache			

subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	4 / 17 (23.53%)
occurrences (all)	2	0	5
Hypoaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	2 / 17 (11.76%)
occurrences (all)	0	0	2
Post herpetic neuralgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Somnolence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Hyperleukocytosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Lymphopenia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Iron deficiency anaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Deafness			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Exophthalmos subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Lacrimation increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Gastrointestinal disorders			
Anorectal discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Ascites subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Diarrhoea			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	4 / 17 (23.53%)
occurrences (all)	0	0	12
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Epigastric discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	0 / 17 (0.00%)
occurrences (all)	2	1	0
Odynophagia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Salivary gland pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Stomatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Toothache			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Tongue geographic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Skin and subcutaneous tissue disorders			
Hyperhidrosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Acne subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Actinic keratosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	2 / 17 (11.76%) 2
Blister subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Dermatitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Dermatitis bullous subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Night sweats subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Pruritus subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	1 / 3 (33.33%) 1	2 / 17 (11.76%) 2
Rash subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 2	1 / 3 (33.33%) 1	1 / 17 (5.88%) 1
Rash macular subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0

Skin haemorrhage subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Vitiligo subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Skin erosion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Renal and urinary disorders Chronic kidney disease subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Nocturia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Endocrine disorders Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Thyroiditis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0
Hyperthyroidism subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 17 (5.88%) 1
Musculoskeletal and connective tissue disorders Muscle spasms subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 17 (0.00%) 0

Arthralgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	4 / 17 (23.53%)
occurrences (all)	0	0	4
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Bone pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Flank pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Skin infection			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Pneumonia aspiration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Myiasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Herpes zoster			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Gingivitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	4 / 17 (23.53%)
occurrences (all)	0	0	4
Viral infection			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	2 / 17 (11.76%)
occurrences (all)	0	0	3
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	4 / 17 (23.53%)
occurrences (all)	1	0	4
Hypercalcaemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	2 / 17 (11.76%)
occurrences (all)	1	0	2
Hypokalaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Hypophosphataemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Hyponatraemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 July 2020	The main purpose of AM1 was to add the IND number.
27 January 2021	The main purpose of AM2 was to clarify existing language, provide country specific requirements, and to remove sections that were not applicable to the study.
04 June 2021	The main purpose of AM3 was to address agency feedback and provide updated language to the pembrolizumab dose modification portion of the study.
02 February 2023	The main purpose of AM4 was to allow ongoing participants to transfer to another sponsored protocol to continue receiving pembrolizumab, incorporate previously released Protocol Clarification Letters, and update the Sponsor corporate name.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
25 July 2023	This study was terminated due to business reasons.	-

Notes:

### Limitations and caveats

None reported